Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions

Annals of the Rheumatic Diseases

Volumn 73, Issue 8, 2014, Pages 1495-1499

  Johnsson, Hanna ^a   Panarelli, Maurizio ^a   Cameron, Allan ^b   Sattar, Naveed ^c  

^a NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

CARDIOVASCULAR DISEASE; INFLAMMATION; LIPIDS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HUMANS; INFLAMMATION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84903880861     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203293     Document Type: Article

References (20)

1. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
4. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-5. (Pubitemid 32739094)
5. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9. (Pubitemid 38129749)
6. Trompet S, Jukema JW, Katan MB, et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 2009;170:1415-21.
7. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7.
8. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
9. Rappaport BA. Overview of the July 29, 2008 AAC Meeting to Discuss BLA 125276 for tocilizumab for the treatment of moderately to severely active rheumatoid arthritis (RA). FDA, 2008. http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4371b1-01-FDA.pdf.
10. Wergeland R, Oyen O, Bentdal O, et al. MicroCRP: a highly sensitive CRP method applied in the monitoring of renal allograft recipients. Scand J Clin Lab Invest 1999;59:405-16.
11. R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0. http://www.R-project.org/.
12. Bourdel-Marchasson I, Laksir H, Puget E. Interpreting routine biochemistry in those aged over 65 years: a time for change. Maturitas 2010;66:39-45.
13. Kushner I. C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001;68:535-7.
14. MacLean DR, Petrasovits A, Connelly PW, et al. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999;15:434-44. (Pubitemid 29224875)
15. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. Can Med Assoc J 2007;176:S1-44.
16. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91. (Pubitemid 29379933)
17. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96. (Pubitemid 38802622)
18. Packard CJ, Slater HR, Shepherd J. The reticuloendothelial system and low density lipoprotein metabolism in the rabbit. Biochim Biophys Acta 1982;712:412-19. (Pubitemid 13227606)
19. Peters MJ, Voskuyl AE, Sattar N, et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract 2010;64:1440-3.
20. Albert MA, Danielson E, Rifai N, et al. RINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70. (Pubitemid 32606333)